True Health Medical (02697) Minimally Invasive Interventional Surgery Siasun Robot&Automation Embraces the "15th Five-Year Plan" Policy Window, Product Hospital Admission Pace Expected to Accelerate

Title context: True Health Medical (02697) Minimally Invasive Interventional Surgery Siasun Robot&Automation Embraces the "15th Five-Year Plan" Policy Window, Product Hospital Admission Pace Expected to Accelerate Text: Recently, the Ministry of Industry and Information Technology and nine other departments jointly issued the "15th Five-Year Plan for Pharmaceutical Industry Development," mapping out the route for the pharmaceutical industry over the next five years. The plan proposes that by 2030, the cumulative number of Innovative Medical Management devices approved for market launch shall be no fewer than 200, and in the direction of intelligent medical devices, it explicitly supports "multimodal AI surgical navigation and positioning systems, specialized and lightweight minimally invasive interventional surgery Siasun Robot&Automation and other therapeutic equipment." This segmented direction explicitly named for support in the field of intelligent medical devices under the plan is precisely the main business in which Hong Kong-listed company True Health Medical (02697) is deeply engaged. The company's percutaneous puncture surgery Siasun Robot&Automation includes four models: TH-S1, TH-S, TH-S Pro, and TH-SA. According to the interim report, all four models have obtained Class III medical device registration certificates from the National Medical Products Administration, and the number of approvals ranks first among domestic peers; among them, TH-S was recognized by the National Medical Products Administration as "domestically pioneered," and the navigation and positioning microwave ablation system TH-X MW was recognized as "internationally pioneered." The company's product line is precisely aligned with the upgrading direction proposed in the "15th Five-Year Plan" for innovative drug and device R&D toward "pioneering, breakthrough, and disruptive" development, and has already extended into the frontier field of extracorporeal organ support. There are also policy levers in the commercialization stage. The plan proposes to "optimize hospital admission processes and incentive measures," "improve pricing, payment, and usage policies," and "vigorously develop commercial health insurance," directly targeting the application chain of innovative devices from approval to hospital admission. True Health Medical's products have entered more than 100 medical institutions and completed over 8,000 surgeries; according to China Insights Consultancy data, in 2025 the company ranked first nationwide in both shipment volume and revenue in China's percutaneous puncture surgery Siasun Robot&Automation market. At the end of August, the company also announced the signing of a sales contract worth nearly RMB 100 million for the sale of puncture surgery navigation and positioning systems, with products to be delivered successively in the near future. In terms of regional layout, the plan proposes building a high-end medical device industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area, and explicitly relies on institutional advantages such as the "Hong Kong and Macao Medicine and Equipment Connect" to build a "globally renowned high-end medical device R&D center." True Health Medical is headquartered in the Hengqin Guangdong-Macao Deep Cooperation Zone, placing it within the Greater Bay Area's medical device R&D and manufacturing chain, and it can leverage Macao's platform and international resources to expand into overseas markets. In addition, the plan lists "deepening AI-enabled upgrading" as a key task, and proposes building a trusted data space for pharmaceutical and health care and accelerating the development of vertical large models and intelligent agents for the pharmaceutical sector. Surgical Siasun Robot&Automation is an important direction for AI implementation in diagnosis and treatment. True Health has previously reached a strategic cooperation with the Tianjin Embodied Intelligence Innovation Center, jointly tackling key challenges around Siasun Robot&Automation vision and multimodal perception and other directions. From qualification recognition to hospital admission ramp-up, from regional layout to intelligent upgrading, the policy direction and the company's main business are highly aligned across four dimensions. For a minimally invasive interventional Siasun Robot&Automation company whose products have already entered the early ramp-up stage of commercialization, the "15th Five-Year Plan" brings not only directional guidance, but also a time window to accelerate hospital admission and volume ramp-up. Beyond surgical Siasun Robot&Automation, True Health Medical's extracorporeal organ support platform centered on normothermic organ perfusion is also advancing in parallel.